Brief: Tcr2 Therapeutics Reports Qtrly Net Loss Per Share Attributable To Common Stockholders, Basic And Diluted $4.85
13/05/2019 22:49
May 13 (Reuters) - Tcr2 Therapeutics Inc TCRR.O :
* TCR2 THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL
RESULTS
AND PROVIDES CORPORATE UPDATE
* INITIATED PHASE 1/2 CLINICAL TRIAL FOR TC-210, TCR(2)'S
LEAD
PRODUCT CANDIDATE TARGETING MESOTHELIN EXPRESSING SOLID TUMORS
* TCR2 THERAPEUTICS- ON TRACK TO FILE AN IND FOR TCR(2)'S
LEAD
HEMATOLOGY PRODUCT CANDIDATE, TC-110, IN PATIENTS WITH CD19+
NON-HODGKIN LYMPHOMAS & LEUKEMIAS IN 2H 2019
* QTRLY NET LOSS PER SHARE ATTRIBUTABLE TO COMMON
STOCKHOLDERS,
BASIC AND DILUTED $4.85
Source text for Eikon: ID:nGNX6n1bhh
Further company coverage: TCRR.O
((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview